Swiss competition watchdog probes Novartis over patent use

Company was allegedly attempting to protect skin disease drug against competing products

Swiss company Novartis is being investigated by the Swiss competition commission. Photograph: Reuters
Swiss company Novartis is being investigated by the Swiss competition commission. Photograph: Reuters

The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.

COMCO conducted an early morning raid on the company on September 13th, it said in a statement that did not name Novartis, which subsequently said in its own statement that it was the group under investigation.

"The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation proceedings," COMCO said in a statement.

Novartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of dermatology treatments.

"In connection with this investigation, COMCO representatives visited the company headquarters in Basel," it said.

“The opening of an investigation does not imply any finding of wrongdoing or any financial impact. Novartis is fully cooperating with the authorities and is confident to clarify the legitimacy of its position,” it added. - Reuters

(c) Copyright Thomson Reuters 2022

  • Join The Irish Times on WhatsApp and stay up to date

  • Sign up to the Business Today newsletter for the latest new and commentary in your inbox

  • Listen to Inside Business podcast for a look at business and economics from an Irish perspective